Abbreviations: CD, cluster of differentiation; COX, cyclooxygenase; DMSO, dimethylsulfoxide; HDHA, hydroxydocosahexaenoic acid; HETE, hydroxyeicosatetraenoic acid; IFNγ, interferon gamma; IL, interleukin; FAME, fatty acid methyl esters; FBS, fetal bovine serum; mAb, monoclonal antibody; LO, lipoxygenase; LPS, lipopolysaccharide; 2 LTB, leukotriene B; MFI, mean fluorescence intensity; NK, natural killer; PBMC, peripheral blood mononuclear cells; PI, propidium iodide; PMA, phorbol 12-myristate 13-acetate; Concomitantly, TXB2 and LTB4 in supernatants decreased, while levels of TXB3 and LTB5
accomplished using GC solution software version 2.3 in comparison to previously measured reference standards (BR2, BR4, and Menhaden from Larodan/CPS-Chemie, Aachen, Germany;
Lipid mediator profiles
PBMC (1 10 6 /mL) were cultured in the presence of 100 μM EPA or DHA for 19 h and subsequently activated for another 5 h with the stimulation mixture as described above.
Corresponding control cultures contained the according volume of DMSO. Afterwards, 1 mL supernatant was added to 1 mL methanol containing BHT (0.1%) and spiked with an internal standard consisting of 15-HETE-d 8 , PGE2-d 4 and LTB4-d 4 (each 1 μg/mL). After addition of 2 mL 0.1 mM sodium acetate buffer to adjust the pH at 6, and centrifugation, the upper phase was subjected to a solid phase extraction using anion exchange columns (Varian Bond Elute Certify II, Agilent), which were preconditioned with 3 mL methanol, followed by 3 mL 0.01 M sodium acetate buffer containing 5% methanol (v/v; pH 6). The columns were then washed twice with 3 mL methanol/water (1/1, v/v) each. For elution, 2 mL of an ethyl acetate:n-hexane extraction mixture (1/1, v/v) was added. The eluate was evaporated in N 2 at 40°C and the solid residues were dissolved in 50 μL acetonitrile. For HPLC analysis, an Agilent 1200SL system equipped with a Phenomenex Kinentex column and coupled with an Agilent 6460 Triplequad mass spectrometer with electrospray ionization source was used. The solvent system consisted of acetonitrile and aqueous formic acid (0.1%). The elution gradient was started with 5% acetonitrile for 30 s, which was increased within 10 min to 90% and held for 8 min. The injection volume was 7.5 μL and the flow rate was set at 0.4 mL/min. Lipid mediator analysis was performed with dynamic Multiple Reaction Monitoring in negative mode. For the preparation of standards and peak calculation including detailed MRM characterization of all measured compounds see Ref. (21) . Peak integration and signal to noise calculation was accomplished using Agilent MassHunter Workstation Software.
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Statistics
For the statistical analysis of the data concerning concentration-dependent fatty acid effects including cellular fatty acid profiles, Th cell cytokines in the absence or presence of T0070907, and lipid mediator profiles, linear mixed models were used with the concentration of the corresponding fatty acid/cytokine being the dependent variable, while the treatment (DHA vs.
EPA) and the concentration (of DHA/EPA or T0070907) were entered as independent variables (fixed effects). For the lipid mediator profiles, treatment and stimulation condition were used as independent variables. For all models, a random intercept per donor was integrated to control for inter-individual differences. Visual inspection of QQ-plots of the residuals and plots of the residuals vs. fitted response values allowed us to justify the assumptions of the linear mixed models, namely homoscedasticity and normal distribution of the residuals. In cases where the assumption of variance homogeneity could not be met we extended the variance structure of the models by including a treatment specific variance structure. We tested better model fit of the extended model by means of a likelihood ratio test (LRT). If the LRT was significant on the 0.05 level, the model with adapted variance structure was preferred. Statistical analysis was carried out using SAS software 9.2 and R 2.15.0 (R Foundation for Statistical Computing, Vienna, Austria). All other data were compared by means of 2-tailed Student´s t-test using SPSS software version 19.0 (SPSS Inc., Illinois, USA). All data are reported as means ± SEM (or SD as indicated) from at least five independent experiments (unless indicated otherwise).
Significance of difference was set at P < 0.05.
RESULTS
Both EPA and DHA do not affect viability of human leukocytes
First we tested whether incubation with EPA or DHA at high concentration has an impact on the viability of primary lymphocytes and monocytes over a period of 24 h. Compared to the DMSO control, neither EPA nor DHA showed any cytotoxic effect at 100 μM (Fig. 1) . A drop in viability was observed only at concentrations higher than 150 μM (data not shown).
Based on these data, a maximum fatty acid concentration of 100 μM was used in all subsequent experiments. Th cells dose-dependently decreased by up to 81% and 73% to 2.7 ± 0.5% and 4.2 ± 0.9%, respectively (P < 0.001). Simultaneously, the mean fluorescence intensity (MFI) reflecting the cytokine levels on a per cell basis, dose-dependently decreased. DHA also significantly reduced the intracellular content of IL-2 and TNF-α in activated Th cells by 61% and 71% to 7.3 ± 1.2% and 7.5 ± 1.2%, respectively (P < 0.001). The reduction in cytokine levels caused by DHA treatment was significantly weaker than that ascertained for EPA (P = 0.005 for IL-2 and P = 0.032 for TNF-α) at all concentrations tested. Correlation analysis revealed a stronger negative association between the cellular uptake of EPA in PBMC and the reduction in the IL-2 and TNF-α positive Th cell population, respectively, than DHA (Fig. 2 c) . Regarding the Th cell population positive for IL-4, a signature cytokine produced by Th2-type T cells (23), also a 12 significant fatty acid-mediated and concentration-dependent decrease was found (P = 0.002).
However, the reduction observed after incubation with EPA tended to be more pronounced than in the presence of DHA (P = 0.087; Fig. 2 a) . The fatty acid-mediated inhibition of cytokine production in Th cells was not general, since neither EPA nor DHA affected the level of IFN-, classically characterizing the Th1 lineage (23), at any tested concentration (Fig. 2 a) .
Both EPA-and DHA-mediated cytokine effects involve PPAR R To investigate whether the fatty acids exert cytokine expression reducing effects via a PPAR R ligand-like action, cells were pre-treated with the selective PPAR R antagonist T0070907 in different concentrations before 100 μM EPA or DHA and the alloreactive stimulation mixture were added. At the example of IL-2 and TNF-α, in both EPA and DHA treated cultures, the reduced cytokine positive Th cell population dose-dependently re-expanded in the presence of T0070907 (P < 0.001 for both IL-2 and TNF-α; Fig. 3 ). These results clearly implicate that PPAR R was involved as a mediator of the anti-inflammatory fatty acid effect.
Both EPA and DHA do not affect the expression of the T cell activation marker CD69
Mitogen activation of PBMC resulted in a significant increase in the expression of the activation marker CD69 on T cells. In the presence of PMA/ionomycin, the percentage of CD69 + rapidly increased from < 1% to > 95% of CD3 + lymphocytes (data not shown). Neither EPA nor DHA altered this percentage at any tested concentration. Likewise, the corresponding MFI remained unaltered (data not shown). In order to evaluate whether any fatty acid effect might have been overlaid by the strong stimulation effect, we gradually reduced the PMA concentration to one tenth of the initially used 2.5 ng/mL. However, the percentage of Both EPA and DHA have no effect on TNF-α and IL-6 production in monocytes
We next measured the levels of TNF-α and IL-6, since these cytokines are the most important produced by monocytes and macrophages. Their over-expression is implicated in several inflammatory conditions, e.g., in the context of the acute phase response (25). Upon activation by LPS, 71.8 7.5% of the CD14 + cell population were found to be TNF-α positive and 19.5
6.0% expressed IL-6 (Fig. 6 ). Since both EPA and DHA exerted a strong inhibition on the expression of pro-inflammatory cytokines, such as TNF-α, in Th cells, it was surprising that the percentages of TNF-α and IL-6 positive monocytes remained completely unaffected in the presence of EPA and DHA at 100 μmol/L (or less, data not shown), respectively ( Fig. 6 ).
Cellular incorporation of both EPA and DHA is negatively associated with arachidonic acid
Since the strong reduction in TNF-α was clearly associated with the cellular incorporation of EPA and DHA ( Fig. 2 c) , but only present in the T cell population, we took a closer look at other than cytokine effects. We therefore determined the impact of EPA and DHA on the 14 metabolism of arachidonic acid whose derivatives are crucially involved in inflammation and known to frequently counteract those derived from EPA and DHA (26).
The base levels of EPA and DHA in native primary PBMC were comparatively low (0.3 0.1% and 2.1 0.2% of total FAME, respectively). Stearic acid (C18:0) was identified as main fatty acid (29.5 0.7% of total FAME) followed by palmitic acid (C16:0; 15.3 0.8%) and arachidonic acid (C20:4n-6; 10.4 1.2%). The increase in the proportion of EPA within the cellular lipid fraction, which almost exclusively consists of phospholipids (see online supplementary material, suppl. Fig. 1 ), entailed a dose-dependent reduction in the percentage of C20:4n-6 (P < 0.001), while the main fatty acid C18:0 (31.3 1.6% at 100 μM EPA) did not quantitatively change (Fig. 7) . Interestingly, the reduction of n-6 PUFA in sum (from 24.2
1.6% to 18.9 0.6% at 100 μM EPA, P < 0.05, 2-tailed Student´s t-test) was solely due to the decrease in C20:4n-6, since the percentages of C18:2n-6, C18:3n-6, C22:2n-6 and C22:4n-6 remained unaltered (data not shown). DHA likewise dose-dependently caused a drop in the proportion of C20:4n-6 (Fig 7) . This DHA-caused effect tended to be less pronounced than that seen for EPA (P = 0.087). However, the cellular enrichment of DHA in response to the supplementation was disproportionately higher compared to EPA (17.5 2.3% vs. 7.4 1.7%
at 100 μM, Fig. 7 ), mainly at the expense of SFA (in sum 46.3 2.2% at 100 μM DHA, P < 0.01 vs. both ctrl: 55.5 2.6% and 100 μM EPA: 56.8 3.7%, 2-tailed Student´s t-test), in particular of C18:0 (P = 0.003 vs. EPA, Fig. 7 a) . For C18:0, an interaction effect between fatty acid treatment and concentration was found (P = 0.008). However, as DHA usually is in sn-2 position, while C18:0 is positioned at sn-1, it is unlikely that DHA has replaced C18:0 in the phospholipids but rather in neutral lipids that were not sorted out herein.
EPA inhibits COX-2 expression in monocytes and formation of arachidonic acid oxygenation products stronger than DHA
Since the drop in C20:4n-6 was likely not due to its increased catabolism (percentages of shorter chain n-6 fatty acids remained unaltered), we next examined whether an increased metabolism, e.g. via cyclo-or lipoxygenation, took place.
Upon stimulation, the formation of bioactive lipid mediators deriving from C20:4n-6 such as PGE2, TXB2 (both metabolized by COX-2), LTB4 (generated via 5-LO pathway) and 12-HETE (generated via 12-LO pathway), often causally involved in pathophysiological processes (27), increased (Fig. 8 a) . At 100 μM, EPA, clearer than DHA, prevented this increase (significant for TXB2: P = 0.021 vs. ctrl, and LTB4: P = 0.017 vs. ctrl, Fig. 8 a) . In accordance, COX-2 abundance in stimulated monocytes decreased in the presence of EPA (Fig. 8 b, c) .
However, this reduction was only by trend (P = 0.1, 2-tailed Student´s t-test).
Increase in both EPA-and DHA-derived lipid metabolite formation is independent of stimulation
In contrast to the arachidonic acid derived cyclo-and lipoxygenation products, the corresponding EPA products, namely TXB3 (COX-2) and LTB5 (5-LO), augmented significantly (Fig. 9 a) . Interestingly, the increase in EPA metabolite formation was independent of stimulation. Thus, we supposed that the presence of EPA sufficed to activate the oxygenation pathway. Indeed, here we show that COX-2 expression was induced by 100 μM EPA, but not DHA, in monocytes, even in the absence of any stimulant (P = 0.012, Fig. 9 b) .
COX-1 expression in monocytes was low (0.2-0.8% of CD14 + ) and unaffected by either fatty acid treatment or stimulation (data not shown).
Moreover, we detected a variety of monohydroxy derivatives in the supernatants of unstimulated and stimulated cultures after 24 h incubation with the fatty acids. Of the numerous HEPE generated from EPA, 18-HEPE, which can be further metabolized to the inflammation dampening resolvins of the E-series (28), was the predominant with 171.5 7.5 ng/mL (Fig. 9 c). Monohydroxy products from DHA were likewise abundantly detectable. Beside 4-, 20-, 17-, 8-, 7-and 11-HDHA (quantitatively in descending order; Fig. 9 d) , also 10-, 13-and 16-HDHA were found in relevant quantity (data not shown), accounting for a total HDHA amount of 936.2 16 326.6 ng/mL. Moreover, DHA gave rise to Resolvin D1 (RvD1, Fig. 9 d) , a lipoxygenated trihydroxy position isomer with high anti-inflammatory potential (29). Likewise, alloreactive stimulation of PBMC did not further increase hydroxy product formation (Fig. 9 c, d ). Analysis of the medium supplemented with EPA or DHA in increasing concentrations but without PBMC revealed that HEPE as well as HDHA and subsequent RvD1 formation occurs nonenzymatically (see online supplementary material, suppl. Fig. 2 ).
DISCUSSION
Th cells and monocytes are intrinsically involved in adaptive and innate immune responses.
The present study aimed at distinctively elucidating the contribution of these two key mediators of cellular immunity to the immunomodulatory effect of EPA and DHA. For this purpose, we focussed on the early production of cytokines and lipid mediators, since these strategies belong to the first being pursued in the acute state of defence.
Herein, we show that both EPA and DHA, but DHA to a lesser extent than EPA, dosedependently decreased the intracellular amounts of immunostimulatory cytokines in Th cells.
The extent of cytokine reduction was cytokine specific, affecting some (IL-2, TNF-α, IL-4), but not others (IFNγ, Fig. 2 ). This finding corroborates previous reports on an EPA-mediated strong suppression of IL-2, whereas other cytokines such as IFNγ remained unaltered (30). 18 on one hand, and pre-treatment of the cultures with the selective PPARγ antagonist T0070907
Induction of IL-2 production in
(41) largely reverted the effect EPA and DHA on the other (Fig. 3) , it is plausible that the fatty acids acted at least in part through PPARγ. Moreover, our results are in line with previous data on anti-inflammatory effects exerted by EPA and DHA via activation of PPARγ (42). However, it has also been shown that n-3 LC-PUFA PPARγ-independently decrease activation of NF-κB in immune competent cells (43).
A second mechanism underlying an altered T cell function is that n-3 LC-PUFA induce biophysical and biochemical changes within the cell membrane affecting both detergentinsoluble and non-raft membrane domains (44) (Fig. 4) . In the latter study, however, confined to the MFI, which is related to the number of CD69 molecules expressed per T cell, a DHAdependent inhibitory effect was shown, that we did not observe. Nevertheless, although the EPA [μM] ctrl 25 50 100
DHA [μM] C22:6n-3 C20:5n-3 C16:0 C20:4n-6 C18:0
Main effects C16:0 C18:0 C20:4n-6 C20:5n-3 C22:6n-3
Concentration P = 0.034 P = 0.067 P < 0.001 P < 0.001 P < 0.001 FA treatment P = 0.099 P = 0.003 P = 0.087 P = 0.001 P < 0.001
Interaction
Conc × treat P = 0.631 P = 0.008 P = 0.760 P < 0. Fig. 9 
